ライフサイエンスコーパス: therapy with

1 during induction and augmented postinduction therapy with 18 Gy of cranial radiation.

2 dscape of non-small-cell lung cancer (NSCLC) therapy, with 2 approvals from the US Food and Drug Admi

3 erapy for 2 weeks, followed by consolidation therapy with 200 mg/day for 8 weeks.

4 r in addition to bone scanning, radionuclide therapy with (223)Ra may be more effective and have more

5 dian age of 73 y who underwent 307 cycles of therapy with (223)RaCl2 were analyzed.

6 per week for 15 weeks, followed by combined therapy with 250 mg intravenous REP 2139 and 180 mug sub

7 Thus, therapy with 2DG to limit glucose utilization caused mic

8 apy, rifampicin monotherapy, and combination therapies with 3 to 4 months of isoniazid and rifampicin

9 easy-to-control asthma were defined as daily therapy with 500 mug of fluticasone or greater with or w

10 patients received somatostatin radiopeptide therapy with (90)Y-DOTATOC or (177)Lu-DOTATOC.

11 es were observed due to patient condition or therapy, with 96.1% and 99.3% glucose results meeting th

12 ed as possible targets for weight management therapies, with a preponderance of studies focusing on t

13 atients received HDCT as third-line or later therapy with a 2-year PFS of 49% (95% CI, 36% to 61%).

14 three patients received HDCT as second-line therapy with a 2-year PFS of 63% (95% CI, 57% to 68%), a

15 notherapy, individuals receiving combination therapy with a baseline eGFR of 60 ml/min per 1.73 m(2)

16 es against each other, including combination therapy with a biologic and immunomodulator compared to

17 t least 16 years that compared psychological therapy with a control intervention or usual treatment w

18 al-chamber, 41.3%; cardiac resynchronization therapy with a defibrillator [CRT-D], 38.9%).

19 umor at diagnosis, during therapy, and after therapy with a histologic response and event-free surviv

20 tment of TB requires six months of multidrug therapy with a mixture of broad spectrum and mycobacteri

21 d the efficacy and tolerance of the standard therapy with a potentially less toxic combination consis

22 on triple therapy and 8 weeks of maintenance therapy with a proton pump inhibitor; and 4) patients re

23 ver 1 year in subjects randomized to medical therapy with a sham procedure (right heart catheterizati

24 Of 3949 eligible participants, 16% started therapy with a statin, 11% with an ACEI/ARB, and 5% with

25 Induction therapy with a T cell-depleting agent followed by mycoph

26 Therapy with a Trk inhibitor together with gemcitabine a

27 tis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were ran

28 Gene therapy with a virus encoding Salv short hairpin RNA imp

29 tive and promising candidate for radioligand therapy, with a favorable preliminary safety profile and

30 Shot provides an overview of CLL biology and therapy, with a focus on genetics and microenvironmental

31 ts had received a median of 3 prior lines of therapy, with a previous hematologic CR in only 5 patien

32 s is important as it can enable personalized therapy with abatacept, a CTLA-4 mimetic, and inform gen

33 Survival on original therapy with acceptable quality of life was also more li

34 Thus, systemic therapy with activated MSC may be an effective new, non-

35 Immune responses in gene therapy with adeno-associated virus (AAV) vectors have b

36 g-term microbiologic outcomes of periodontal therapy with adjunctive antibiotics either in T1 or T2 w

37 Most surgical patients received trimodal therapy with adjuvant CRT.

38 y improve the treatment efficacy of combined therapy with ADT and vaccination.

39 TAE therapy with aflibercept is a rational strategy to reduc

40 All participants received supportive therapy with albumin.

41 Depleting antibody induction therapy with alemtuzumab and Thymoglobulin appear equall

42 Current therapies with all-oral direct-acting antiviral agents a

43 tionally, we found that response to targeted therapy with all-trans retinoic acid in vivo was depende

44 The duration of therapy with AmB (14 vs 11 days, p=0.05) and 5-FC (7.5 v

45 death sooner than 24 h after the index date, therapy with an active antibiotic for at least 2 days wh

46 MZL of all subtypes who received >/=1 prior therapy with an anti-CD20 antibody-containing regimen we

47 ng-guided catheter-directed endothelial cell therapy with an intraportal technique for the treatment

48 ment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or letrozole.

49 Current standard therapy with angiotensin-converting enzyme inhibitors an

50 ic strategy to be implemented in combination therapies with anti-CD20 monoclonal antibodies and open

51 Antiangiogenic therapy with antibodies against VEGF (bevacizumab) or VE

52 ongoing clinical trials that combine cancer therapies with antimalarial drugs for the treatment of a

53 comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed wi

54 ing clinically available, anti-proliferative therapies with ART could result in functional cure withi

55 Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatm

56 erwent aggressive titration of vasoactive HF therapies with assessment of central aortic waveforms an

57 or older; had been treated with two lines of therapy (with at least a partial response after second-l

58 study to report results of a PD-L1-targeted therapy, with atezolizumab treatment resulting in a clin

59 arge B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response

60 Our results show that therapy with Aza is an effective means of controlling a

61 Hence, therapy with Aza, which acts mainly by its effects on Tr

62 Conversely, nonbiologic combination therapy with azathioprine exhibited the highest DR owing

63 Effects of combination therapy with benznidazole and posaconazole have not been

64 tomatic patients with obstruction is medical therapy with beta-blockers and calcium antagonists.

65 sical or emotional stress, for which current therapy with beta-blockers is incompletely effective.

66 bevacizumab, many specialists might initiate therapy with bevacizumab when visual acuity is good (ie,

67 on of early immunosuppression or combination therapy with biologicals in high-risk patients, combined

68 ve Crohn disease who were scheduled to begin therapy with biologics (infliximab or adalimumab) were i

69 therapy and which should receive combination therapy with both NUC and pegylated interferon remain un

70 on emission tomography (PET)-adapted salvage therapy with brentuximab vedotin (BV) and augmented ifos

71 ednisone 40 mg/d for 2 weeks and maintenance therapy with budesonide/formoterol 400/12 mug twice dail

72 In this phase 2 study of PET-adapted therapy with BV and augICE for relapsed/refractory HL, b

73 ggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1beta

74 8 to <70 years on suppressive antiretroviral therapy with CD4+ counts >350 cells/muL and detectable p

75 Cellular therapy with CD4FOXP3 T regulatory (Treg) cells is a pro

76 Among postmenopausal women, hormone therapy with CEE plus MPA for a median of 5.6 years or w

77 Physicians might consider definitive therapy with cefazolin for these infections.

78 This study compared definitive therapy with cefazolin vs nafcillin or oxacillin among p

79 re positive for MSSA and received definitive therapy with cefazolin, nafcillin, or oxacillin.

80 nts, 1163 (37%) patients received definitive therapy with cefazolin.

81 d Prevention (CDC) currently recommends dual therapy with ceftriaxone and azithromycin for gonorrhea

82 To investigate the association of biological therapy with changes in coronary artery disease progress

83 Neoadjuvant therapy with chemotherapy or chemoradiotherapy has suppl

84 The outcome of therapy with chimeric Ag receptor (CAR)-modified T cells

85 HNSCC patients who may benefit the most from therapy with CHK inhibitors.

86 Dabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity a

87 tients with PD receiving stable dopaminergic therapy with coexistent EDS, as assessed by an Epworth S

88 ponse after up-front treatment and frontline therapy with combined bortezomib, melphalan, and dexamet

89 Patients initiating therapy with common medications for chronic diseases (di

90 In preclinical studies, combination therapy with compound 7 and gammadelta T cells prolonged

91 ls, published in any language, comparing ICD therapy with conventional care and reporting mortality o

92 To compare ICD therapy with conventional care for the primary preventio

93 ed worsening in respiratory health requiring therapy with corticosteroids and/or antibiotics, and sev

94 of the lower GI tract, who do not respond to therapy with corticosteroids, have a dismal prognosis.

95 Locoregional therapy with curative intent (CLRT) followed by salvage

96 ale sex, multiple comorbidities, concomitant therapy with cyclosporine, and a high Psoriasis Area and

97 igned to receive two cycles of consolidation therapy with cytarabine 100 mg/m(2) daily for 5 days, et

98 Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a si

99 failed to achieve SVR on previous NS5A-based therapy with daclatasvir (DCV) plus pegylated interferon

100 The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation the

101 0 copies/mL for 6 months or longer on triple therapy with darunavir/ritonavir and 2 nucleos(t)ides (t

102 ssess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared

103 Dual therapy with darunavir/ritonavir and lamivudine demonstr

104 /ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides f

105 to receive standard chemotherapy (induction therapy with daunorubicin and cytarabine and consolidati

106 eactions were compared following single-dose therapy with DEC or IVM to assess whether these reaction

107 intervention studies have shown that enteral therapy, with defined formula diets, helps children with

108 tors of response to short-course combination therapies with direct-acting antiviral drugs that might

109 Interferon-free, guideline-tailored therapy with direct-acting antivirals is highly effectiv

110 lic parameters, demonstrating that combining therapies with distinct mechanism(s) can alleviate advan

111 T-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) according to sex and t

112 e ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) registry.

113 D ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was a prospective, mul

114 T-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) were stratified accord

115 APT-DES [the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents], THIN [The Health Impr

116 HIV-1) infection currently requires lifelong therapy with drugs that are used in combination to contr

117 RATIONALE: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acti

118 h three cycles of RVD and then consolidation therapy with either five additional cycles of RVD (350 p

119 C were randomly assigned to receive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1

120 erapy will potentially complement definitive therapy with either neo- or adjuvant therapy to improve

121 remission following completion of front-line therapy with either rituximab plus cyclophosphamide, dox

122 x by using endoscopic resection or radiation therapy, with either leading to similar outcomes.

123 We combined standard immunosuppressive therapy with eltrombopag in previously untreated patient

124 before and 6 months after the initiation of therapy with elvitegravir, cobicistat, emtricitabine, an

125 with oral selinexor at 35 mg/m(2) is a safe therapy with encouraging and durable anticancer activity

126 ng-term efficacy and safety during long-term therapy with evolocumab, a monoclonal antibody against p

127 There is a need for hepatitis C virus (HCV) therapies with excellent efficacy across genotypes and i

128 ity lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvast

129 ntensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProv

130 Replacement therapy with factor VIII (FVIII) is used in patients wit

131 limited effectiveness as single agent cancer therapies, with feedback mechanisms inherent to the sign

132 of colon cancer xenografts to antiangiogenic therapy with functional and molecular US imaging.

133 Therapy with genetically modified autologous T cells has

134 sponded to at least 3 months of conventional therapy with glucocorticosteroids, thiopurines, or metho

135 n NS3 from GT1a-infected patients who failed therapy with grazoprevir (in combination with elbasvir,

136 ore likely to be alive at 1 year on original therapy with >/=75-m improvement in 6-minute walk distan

137 ti-vascular endothelial growth factor (VEGF) therapy with >1 year follow-up at an academic retina ser

138 ts Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) compares the HM3 LVAS with the

139 outcomes have been reported after definitive therapy with hematopoietic stem cell transplantation and

140 We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) mon

141 l E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m(2)) im

142 aunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaur

143 mine the association of diabetes and insulin therapy with hospitalization for infection and 28-day mo

144 In the present study, therapy with HQ has been proven to be safe, with a relat

145 RT patients who had progression after prior therapy with ibrutinib.

146 ges in TH17 cell functions before and during therapy with IL-1beta-blocking drugs.

147 Adjuvant therapy with imatinib benefits patients with a high risk

148 nabling combinations of molecularly targeted therapies with immunotherapies that are pharmacologicall

149 e different strategies that combine targeted therapies with immunotherapy approaches, and discuss pas

150 based on natriuretic peptide levels ("guided therapy") with inconsistent results.

151 rogeneity and predicted patient benefit from therapy with increased sensitivity.

152 arinic antagonist (LAMA), licensed as triple therapy with inhaled corticosteroid and long-acting beta

153 r signaling pathways, suggesting combination therapies with inhibitors of these pathways.

154 In melanoma, therapies with inhibitors to oncogenic BRAF(V600E) are h

155 Combination therapy with intranasal corticosteroid plus intranasal a

156 ds in the AH from Rb eyes undergoing salvage therapy with intravitreous injection of melphalan, the r

157 He began systemic therapy with ipilimumab and nivolumab.

158 after, all the patients received maintenance therapy with itraconazole.

159 Patients in both groups received maintenance therapy with lenalidomide for 1 year.

160 er, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone

161 tive schedule of extended adjuvant endocrine therapy with letrozole, including intermittent administr

162 ys; group A) or a 10-day modified sequential therapy with Levofloxacin 500 mg id instead of Clarithro

163 ard treatment is thyroid hormone replacement therapy with levothyroxine.

164 iral suppression is easily achievable by NUC therapy, with limited adverse reactions.

165 2499 patients underwent primary proton beam therapy, with local tumor control and globe preservation

166 rom 16% at diagnosis to 31% post-neoadjuvant therapy, with loss of LBM (-3.0 +/- 5.4 kg, P < 0.0001),

167 ncontrolled IOP on maximum-tolerated medical therapy, with medicated IOP >/=20 and </=35 mm Hg and vi

168 against drug-resistant strains in adjunctive therapy with meropenem, a standard-of-care antibiotic, c

169 7 adults with bipolar disorder who initiated therapy with methylphenidate between 2006 and 2014.

170 Photodynamic therapy with microneedle pretreatment at a 20-minute ALA

171 Combining omalizumab therapy with milk OIT led to distinct alterations in bas

172 promising lead for treating VL as an adjunct therapy with miltefosine.

173 rent-delivered CBT or solution-focused brief therapy, with minimisation for age, sex, anxiety severit

174 Reinitiating therapy with moderate-intensity statins, down-titration,

175 d clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up.

176 -year follow-up, 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy

177 Importantly with respect to empirical therapy with new beta-lactamase inhibitor combinations s

178 Here we find that intratumoral therapy with Newcastle disease virus (NDV), in addition

179 ent (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m(2) intravenous rituximab

180 phase I dose-escalation study of concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) in pa

181 r overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab

182 ized controlled trials comparing IBD medical therapies with no restrictions on language, country of o

183 patients receiving appropriate antimicrobial therapy, with no false-negative cases.

184 and-ship paradigm also benefit from bridging therapy, with no statistically significant difference co

185 ion This study demonstrates that maintenance therapy with norethandrolone significantly improves surv

186 Empiric therapy with OADs was not associated with mortality (haz

187 ned a subset of patients in which adjunctive therapy with omalizumab was associated with attainment o

188 jects most likely to benefit from adjunctive therapy with omalizumab.

189 lial tissues and has implications for cancer therapy with oncolytic adenoviruses.

190 ere randomly assigned to receive maintenance therapy with one infusion of rituximab every 2 months, e

191 level of safety of (177)Lu-PSMA radioligand therapy, with only minimal grade 3 and 4 toxicities repo

192 ctivity to assist the design of CRISPR-based therapies with optimized efficacy and safety.

193 An additional benefit of testosterone therapy (with or without mastectomy) is a reduced risk o

194 on survival of salvage androgen deprivation therapy with or without agents shown to prolong survival

195 Local consolidative therapy with or without maintenance therapy for patients

196 Although cognitive behavioral therapy with or without selective serotonin reuptake inh

197 They often seek hormone therapy, with or without surgery, to improve their gende

198 (AIs) are the preferred first-line endocrine therapy, with or without the cyclin-dependent kinase inh

199 ative effectiveness trial comparing systemic therapy with oral corticosteroids and immunosuppression

200 To test whether therapy with oral iron improves peak exercise capacity i

201 re assessed for their response to 2 weeks of therapy with oral prednisolone.

202 east cancer, and combinations of AR-targeted therapies with other agents have been investigated for o

203 New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed.

204 s support evaluation of this antibody in AML therapy, with particular appeal to patients resistant to

205 Intratumoral therapy with pathogen-associated molecular patterns or r

206 y be possible to develop novel combinatorial therapies with PBD- and tubulysin-based ADC and immuno-o

207 mogene laherparepvec followed by combination therapy with pembrolizumab.

208 h cryosurgery, allowing patients to continue therapy with pembrolizumab.

209 constructed for combined chemo-photothermal therapy with pinpointed drug delivery and release capabi

210 prostate cancer; and compared bone-targeted therapies with placebo, usual care, or other active trea

211 I trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL who

212 ling and is prevented by upfront combination therapy with PLX8394 and either an EGFR or mTOR inhibito

213 chronic hepatitis B patients under long-term therapy with potent nucleos(t)ide analogues is currently

214 ither access therapy alone (group 1), access therapy with PRF (group 2), or access therapy with PRF a

215 therapy with PRF; and 3) group 3 had access therapy with PRF + 1% ALN.

216 access therapy with PRF (group 2), or access therapy with PRF and 1% ALN (group 3).

217 access therapy alone; 2) group 2 had access therapy with PRF; and 3) group 3 had access therapy with

218 llness and 26.7% received rescue oxygenation therapy with prone ventilation, extracorporeal life supp

219 ve (61.6%) and 53 (38.4%) patients initiated therapy with PVA and UPVA, respectively.

220 fractionated administration and combination therapy with radiation sensitizers, chemotherapy, and ot

221 Whether antiandrogen therapy with radiation therapy will further improve canc

222 ntroduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [(90)Y-

223 , and phosphate-buffered saline, combination therapy with RF hyperthermia and chemotherapy induced th

224 id, both as a monotherapy and in combination therapy with rifampicin.

225 in lymphoma (HL) is essential for optimizing therapy with risk-adapted approaches.

226 Combination therapy with rituximab enhanced activity in preclinical

227 The benefits of B-cell-targeted therapy with rituximab have been observed in MG; however

228 In intervention studies, therapy with rosuvastatin significantly reduced venous t

229 ng approach has also been pursued for dengue therapy, with several compounds tested in clinical trial

230 ERK1/2 pathway inhibitors are used in cancer therapy, with severe and noncharacterized ocular side ef

231 s administered intensity-modulated radiation therapy with simultaneous integrated boost (SIB-IMRT) vs

232 ngineered vascular grafts for cardiovascular therapies with small caliber vessels.

233 have emerged as major targets for selective therapy with small-molecule inhibitors.

234 ensitizer and light irradiation, combination therapy with SN-38-encapsulated nanoporphyrin micelles (

235 rapy (photothermal-, photodynamic- and chemo-therapy) with SN-NPM demonstrated dramatically enhanced

236 tional cohort study, direct-acting antiviral therapy with SOF/ledipasvir, ombitasvir/paritaprevir/rit

237 viously failed direct-acting antiviral-based therapies with sofosbuvir-velpatasvir plus ribavirin for

238 nfection before, during, and after antiviral therapy with sofosbuvir and velpatasvir, we found that i

239 Medical therapy with somatostatin analogues, cabergoline, and pe

240 veloping new rationally designed combination therapies with sorafenib.

241 a novel ARAF mutation responsive to targeted therapy with sorafenib.

242 Implantation Trial-Cardiac Resynchronization Therapy) with speckle-tracking data available.

243 the association of preceding antithrombotic therapy with stroke severity and in-hospital outcomes.

244 tudy was to summarize data linking fertility therapy with subsequent cardiovascular outcomes.

245 with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or c

246 ized, controlled trials that compare medical therapy with surgical therapy in patients with type 2 di

247 Therapy with systemic methotrexate did not suffice, as a

248 atients with advanced cirrhosis, but current therapy with systemic vasoconstrictors is ineffective in

249 tive MBC, but one third of patients received therapy with T-DM1 for >/= 6 months, which suggests a cl

250 ere using mouse models, we show that topical therapy with tacrolimus, an anti-T-cell immunosuppressiv

251 potential therapeutic target for combination therapy with TAE.

252 non-Hispanic whites when they initiated AET therapy with tamoxifen (OR, 0.54; 95% CI, 0.31 to 0.93)

253 uate the off-treatment eGFR after 3 years of therapy with telbivudine (LdT) or entecavir (ETV) and to

254 We tested the hypotheses that reperfusion therapy with tenecteplase would be superior to alteplase

255 locally defined viral failure on first-line therapy with tenofovir plus a cytosine analogue (lamivud

256 Continued therapy with teriparatide prevented the appearance of ad

257 rallel-group trial, we evaluated combination therapy with tezacaftor and ivacaftor in patients 12 yea

258 CFTR modulator therapy with tezacaftor-ivacaftor or ivacaftor alone was

259 our aim was to compare the two psychological therapies with the brief psychosocial intervention, we f

260 harmacokinetic profiles could yield improved therapies with the potential of higher efficacy and grea

261 In the C-SURFER study, therapy with the all-oral elbasvir plus grazoprevir regi

262 ffective against HIV in comparison to triple therapy with the antiretroviral (ARV) drugs.

263 Combination therapy with the BRAF inhibitor dabrafenib plus the MEK

264 Photodynamic therapy with the construct was successful in inducing cy

265 y, we evaluate objective response rate after therapy with the gamma-secretase inhibitor PF-03084014 i

266 in uveal melanoma patients after proton beam therapy with the main focus on outcomes according to dif

267 nts were offered salvage radiopharmaceutical therapy with the novel NTR1 antagonist (177)Lu-3BP-227.

268 Molecular bypass therapy with the TK2 products, deoxycytidine monophospha

269 HGF in tumors for planning any HGF-targeted therapy, with the potential to improve clinical outcomes

270 The risk of thrombosis during anticoagulant therapy with these treatments is not well studied but is

271 scular endothelial growth factor (anti-VEGF) therapy, with these participants having baseline visual

272 We have demonstrated gene therapy with this vector by restoring dystrophin express

273 itus, comparing women who received fertility therapy with those who did not.

274 nin-angiotensin-aldosterone system inhibitor therapy with those who were not.

275 Intensive antiplatelet therapy with three agents might be more effective than g

276 ents with leprosy should receive combination therapy with three antibiotics: rifampicin, clofazimine,

277 s with multiple myeloma to receive induction therapy with three cycles of RVD and then consolidation

278 Combining an immunosuppressant therapy with thrombopoietin-receptor agonists may be a g

279 loading and maintenance of dual antiplatelet therapy with ticagrelor and the influence of timing on t

280 r, essential to improve current thrombolytic therapy with tissue plasminogen activator (t-PA).

281 were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo

282 ere randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice dai

283 Although therapy with Trametinib and Dabrafenib was stopped uveit

284 f either pertuzumab or placebo to first-line therapy with trastuzumab and docetaxel for patients with

285 ata are available for the efficacy of triple therapy with two long-acting bronchodilators and an inha

286 mmended components of initial antiretroviral therapy with two nucleoside reverse transcriptase inhibi

287 ta are available for the efficacy of "triple therapy" with two long-acting bronchodilators and an inh

288 eukemia (CML) SCs that is enriched following therapy with tyrosine kinase inhibitors (TKIs).

289 ected patients on suppressive antiretroviral therapy with undetectable viral loads.

290 is have an inadequate response to first-line therapy with ursodeoxycholic acid.

291 e risk of AKI in children during concomitant therapy with vancomycin and 1 antipseudomonal beta-lacta

292 hose, 377 were randomly assigned to hormonal therapy with vigabatrin (186) or hormonal therapy alone

293 sed in 133 (72%) of 186 patients on hormonal therapy with vigabatrin compared with 108 (57%) of 191 p

294 INTERPRETATION: Hormonal therapy with vigabatrin is significantly more effective

295 1:1) by a secure website to receive hormonal therapy with vigabatrin or hormonal therapy alone.

296 on hormonal therapy alone and 17 on hormonal therapy with vigabatrin).

297 hormonal therapy alone and four on hormonal therapy with vigabatrin.

298 of AKI among patients receiving combination therapy with VPT to a matched group receiving VC.

299 In multivariate analysis, therapy with VPT was an independent predictor for AKI (h

300 Further, our data suggest combination therapy with WNT and SHH inhibitors as a therapeutic str